The internationally validated ImmunoscoreTM predicts CRC survival risk by averaging percentile scores of tumor-associated CD3<sup>+</sup> and CD8<sup>+</sup> cell densities, but is limited by increased cost, intra-tumoral heterogeneity and omission of other immunologic variables of importance. The gene discussed is CD8A; the disease is neoplasm.